KD clients, Neupulse, have taken a significant step towards bringing their game-changing solution aimed at tackling Tourette Syndrome (TS) and other tic disorders towards commercialisation. KD have been supporting Neupulse in the design and development of the wrist-worn wearable device which stimulates the median nerve, now realised in working prototype form.
Equally importantly, Neupulse has secured a £2.5 million seed stage investment led by Scottish impact investor Eos Advisory, alongside a consortium including US-based investors, to support ongoing development of the product as it progresses towards manufacture and regulatory approvals in the UK, Europe, and the USA.
Tourettes Syndrome is a condition thought to affect as much as 2% of the world’s child population and 1% of the overall population. Pioneering neuroscience work by Professor Stephen Jackson, and a team at the University of Nottingham Clinical, led to the breakthrough. KD first supported the team by developing and manufacturing devices for use in a 2023 clinical trial, the results of which demonstrated the effectiveness in reducing the instance and severity of tics. You can find out more about this work here.
Paul Cable, CEO of Neupulse, said: “Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals. Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the Tourettes community globally in the years ahead.”
Explore more
